To take an unbiased approach and investigate if triplication of genes other than APP can modulate the development of Down syndrome–Alzheimer’s disease in vivo, we crossed a model of Down syndrome that is aneuploid for chromosome 21 with a mouse that deposits amyloid-β in the brain. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.